clinical trial · NCT07142811
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Viral HepatitisTobevibartElebsiranBulevirtide
brief summary
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
started
Aug 5, 2025
primary completion
Nov 1, 2026
completion
Jul 1, 2030
last updated
Jan 16, 2026
official title
A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol